IQVIA Holdings Inc. (IQV)
NYSE: IQV · Real-Time Price · USD
154.73
+0.12 (0.08%)
At close: Jun 20, 2025, 4:00 PM
155.04
+0.31 (0.20%)
After-hours: Jun 20, 2025, 7:59 PM EDT
IQVIA Holdings Revenue
IQVIA Holdings had revenue of $3.83B in the quarter ending March 31, 2025, with 2.46% growth. This brings the company's revenue in the last twelve months to $15.50B, up 2.84% year-over-year. In the year 2024, IQVIA Holdings had annual revenue of $15.41B with 2.81% growth.
Revenue (ttm)
$15.50B
Revenue Growth
+2.84%
P/S Ratio
1.79
Revenue / Employee
$176,102
Employees
88,000
Market Cap
26.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15.41B | 421.00M | 2.81% |
Dec 31, 2023 | 14.98B | 574.00M | 3.98% |
Dec 31, 2022 | 14.41B | 536.00M | 3.86% |
Dec 31, 2021 | 13.87B | 2.52B | 22.14% |
Dec 31, 2020 | 11.36B | 271.00M | 2.44% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IQV News
- 4 days ago - IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement' - Business Wire
- 9 days ago - IQVIA Launches New AI Agents for Life Sciences and Healthcare - Business Wire
- 10 days ago - IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap? - Benzinga
- 18 days ago - IQVIA Announces Pricing of Senior Notes - Business Wire
- 18 days ago - IQVIA Announces Offering of Senior Notes - Business Wire
- 24 days ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 5 weeks ago - IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Business Wire
- 6 weeks ago - IQVIA: Q1 Earnings Support Steady Optimism - Seeking Alpha